Edit |   |
---|---|
Antigenic Specificity | CD199 (CCR9), Human |
Clone | REA469 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 |
Format | APC-Vio 770 conjugate |
Size | 30 tests in 300 µL |
Concentration | 1:11 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD199 (CCR9) Antibody, anti-human, APC-Vio® 770, REAfinity™. Clone REA469 recognizes the human CD199 antigen, a multi-pass membrane protein which is also known as C-C chemokine receptor type 9 (CCR9) or G-protein coupled receptor 28 (GPR28). CD199 is a receptor for the chemokine thymus-expressed chemokine (TECK) and a member of the G protein coupled receptor family (GPCR). The main function of GPCR family members is to send signals into the cell after the activation of G-proteins and they are known for their roles in inflammation, leukocyte trafficking, and immune differentiation. CD199 subsequently transduces a signal by increasing the intracellular calcium ions level. It influences T cell development at several stages within the thymus. In peripheral blood, CD199 is expressed by naive CD8+ T cells, but not by naive CD4+ T cells. It is furthermore selectively expressed on plasmacytoid dendritic cells of immature phenotype in vivo. Different studies have shown the involvement of the CD199-TECK axis in colorectal, prostate, ovarian, and breast cancers. | Additional information: Clone REA469 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | CCR9, CC-CKR-9, CDw199, GPR-9-6, GPR28, GPR28 |
Gene, Accession # | Gene ID: 10803 |
Catalog # | 130-107-172 |
Price | $151 |
Order / More Info | CD199 (CCR9), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Zaballos, A. et al. (1999) Cutting Edge: Identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162 (10): 5671-5675. | Hadeiba, H. et al. (2008) CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol 9: 1253-1260. | Zhang, Z. et al. (2014) CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma. Oncol. Rep. 31 (4): 1629-1636. |